Longeveron (LGVN) investor relations material

Executive summary

• Advancing four stem cell therapy programs, with a focus on laromestrocel for HLHS, Alzheimer's, pediatric dilated cardiomyopathy, and age-related frailty, and approaching key milestones including a September 2026 HLHS Phase 2b data readout.

• Laromestrocel recognized as a finalist in the XPRIZE Healthspan competition, receiving a $1 million award and highlighting external validation.

• No FDA-approved products; revenue is derived from clinical trials and contract manufacturing, with the latter declining.

• Strategic shift to a capital-efficient, asset-light model, including outsourcing manufacturing and seeking partnerships.

• Three new independent directors joined the board, and the company is actively pursuing strategic partnerships and collaborations.

Financial highlights

• Q2 2026 revenue was $0.3 million, down 10% year-over-year due to absence of contract manufacturing revenue; revenue for the first half of 2026 was $0.7 million, down 2% year-over-year.

• Net loss for Q2 2026 was $6.1 million, up 22% year-over-year; net loss for the first half of 2026 was $10.8 million.

• Cash and cash equivalents stood at $10.1 million as of June 30, 2026, expected to fund operations into Q4 2026.

• General and administrative expenses rose 23% to $3.2 million for Q2 2026, mainly from increased legal and personnel costs.

• Research and development expenses increased 7% to $3.2 million for Q2 2026; R&D expenses for the first half of 2026 were $5.5 million, flat year-over-year.

Outlook and guidance

• Top-line results from the ELPIS II HLHS trial are expected in September 2026, with potential for regulatory submission and partnership discussions if positive.

• Planning for a phase II trial in pediatric dilated cardiomyopathy in 2027, following IND effectiveness in July 2025.

• Current cash is expected to fund operations into Q4 2026; additional capital will be required to continue operations and advance clinical programs.

• Exploring accelerated or traditional approval pathways based on long-term outcomes and seeking strategic partnerships and non-dilutive funding.

• Substantial doubt exists about the ability to continue as a going concern without new financing.